Payment overview · 2025
General Payments
$909.91
42 reported records · 9 companies
Healthcare provider profile · identity verified
Dawn Dean, FNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Primary Care · SPRINGFIELD, MO · NPI 1720386659
Verified facts
What the public records show
CMS Open Payments records show Dawn Dean, FNP received $909.91 in general payments during 2025 across 42 reported records.
ABBVIE INC. accounted for 43.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Symbicort by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $397.81 | 43.7% | 22 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $220.66 | 24.2% | 8 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $156.30 | 17.2% | 5 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $34.78 | 3.8% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $26.01 | 2.9% | 1 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $23.47 | 2.6% | 1 | 2025 |
| Braeburn Inc. | Unresolved — no canonical attribution shown | $19.19 | 2.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.80 | 1.9% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.89 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $909.91 | 42 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $220.66 | 8 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $156.30 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $144.23 | 5 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $135.23 | 6 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $118.35 | 11 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $34.78 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $27.26 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $26.01 | 1 | 2025 |
Source payment records
|
|||||
| VIVITROL Normalized: vivitrol |
Drug | Alkermes, Inc. | $23.47 | 1 | 2025 |
Source payment records
|
|||||
| BRIXADI Normalized: brixadi |
Drug | Braeburn Inc. | $19.19 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.80 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.89 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
34 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 346 | 90 |
| Amlodipine Besylate | Amlodipine Besylate | 311 | 72 |
| Metformin Hcl | Metformin Hcl | 251 | 55 |
| Gabapentin | Gabapentin | 239 | 48 |
| Lisinopril | Lisinopril | 234 | 63 |
| Levothyroxine Sodium | Levothyroxine Sodium | 207 | 40 |
| Omeprazole | Omeprazole | 176 | 42 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 166 | 41 |
| Losartan Potassium | Losartan Potassium | 155 | 38 |
| Pantoprazole Sodium | Pantoprazole Sodium | 150 | 25 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 147 | 14 |
| Baclofen | Baclofen | 146 | 31 |
| Tramadol Hcl | Tramadol Hcl | 144 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 134 | 24 |
| Trulicity | Dulaglutide | 118 | 18 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 116 | 34 |
| Hydrochlorothiazide | Hydrochlorothiazide | 111 | 28 |
| Famotidine | Famotidine | 109 | 27 |
| Trazodone Hcl | Trazodone Hcl | 109 | 27 |
| Tizanidine Hcl | Tizanidine Hcl | 101 | 25 |
| Buspirone Hcl | Buspirone Hcl | 97 | 20 |
| Sertraline Hcl | Sertraline Hcl | 92 | 25 |
| Carvedilol | Carvedilol | 91 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 87 | 23 |
| Simvastatin | Simvastatin | 83 | 15 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 82 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 82 | 21 |
| Diclofenac Sodium | Diclofenac Sodium | 81 | 24 |
| Meloxicam | Meloxicam | 77 | 21 |
| Furosemide | Furosemide | 76 | 17 |
| Potassium Chloride | Potassium Chloride | 75 | 20 |
| Lovastatin | Lovastatin | 74 | 15 |
| Metoprolol Succinate | Metoprolol Succinate | 69 | 22 |
| Montelukast Sodium | Montelukast Sodium | 68 | 14 |
| Tamsulosin Hcl | Tamsulosin Hcl | 67 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 62 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 57 | 14 |
| Allopurinol | Allopurinol | 50 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 49 | 18 |
| Ozempic | Semaglutide | 47 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 47 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 46 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 46 | 14 |
| Jardiance | Empagliflozin | 45 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 45 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 44 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 41 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 41 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 40 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 39 | suppressed |
| Ibuprofen | Ibuprofen | 38 | 11 |
| Incruse Ellipta | Umeclidinium Bromide | 38 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 35 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 34 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 34 | 13 |
| Linzess | Linaclotide | 33 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 32 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 32 | suppressed |
| Lubiprostone | Lubiprostone | 32 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 31 | suppressed |
| Valsartan | Valsartan | 30 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 29 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 28 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 27 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 27 | 14 |
| Celecoxib | Celecoxib | 26 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 25 | 23 |
| Oxybutynin Chloride | Oxybutynin Chloride | 25 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Spironolactone | Spironolactone | 24 | suppressed |
| Glimepiride | Glimepiride | 23 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Mounjaro | Tirzepatide | 22 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 22 | suppressed |
| Prednisone | Prednisone | 21 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 21 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 20 | suppressed |
| Nifedipine Er | Nifedipine | 20 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 20 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 19 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 19 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 19 | suppressed |
| Topiramate | Topiramate | 19 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 18 | suppressed |
| Carbamazepine | Carbamazepine | 18 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Nystatin | Nystatin | 17 | suppressed |
| Rybelsus | Semaglutide | 17 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 16 | suppressed |
| Atenolol | Atenolol | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 15 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 15 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Jublia | Efinaconazole | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 14 | suppressed |
| Eliquis | Apixaban | 13 | suppressed |
| Ezetimibe | Ezetimibe | 13 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 13 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 12 | suppressed |
| Asenapine Maleate | Asenapine Maleate | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Lyrica | Pregabalin | 12 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 12 | suppressed |
| Techlite Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 11 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $909.91 · 42 records | ABBVIE INC. | BREZTRI, BRIXADI, CAPLYTA, Cologuard Collection Kit, Dexcom G6 Transmitter, MAVYRET, Omnipod, QULIPTA, REXULTI, UBRELVY, VIVITROL, VRAYLAR | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error